Cheplapharm AG

CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth

Caroline Jacquin appointed Managing Director of CHEPLAPHARM France SAS

CHEPLAPHARM acquires Roaccutane® from Roche

CHEPLAPHARM opens presence in Tokyo

CHEPLAPHARM succesfully places additional notes in a volume of €300m

CHEPLAPHARM opens swiss subsidiary and wins Agnes Wasem as Managing Director

CHEPLAPHARM places notes in a volume of €750m in challenging market environment

Change in the Management of CHEPLAPHARM

CHEPLAPHARM remains on growth track

CHEPLAPHARM receives growth capital of EUR 550 million from two leading global investors

CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022eplapharm AG:

CHEPLAPHARM CONTINUES PROFITABLE GROWTH TRACK IN 2021 AS WELL

Cheplapharm AG: Jens Rothstein hands over his CFO role to Kia Parssanedjad

Cheplapharm AG: CHEPLAPHARM GMBH ANNOUNCES SUCCESSFUL PRICING OF TERM LOAN B

Cheplapharm AG: TIMETABLE FOR THE PLANNED IPO IS EXTENDED DUE TO UNFAVORABLE MARKET CONDITIONS

Cheplapharm AG: CHEPLAPHARM AG PLANS FRANKFURT STOCK EXCHANGE LISTING IN Q1 2022